Fox Run Management L.L.C. Acquires Shares of 18,195 Fresenius Medical Care AG (NYSE:FMS)

Fox Run Management L.L.C. bought a new stake in Fresenius Medical Care AG (NYSE:FMS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,195 shares of the company's stock, valued at approximately $412,000.

Other institutional investors also recently bought and sold shares of the company. Signaturefd LLC raised its position in Fresenius Medical Care by 16.6% in the fourth quarter. Signaturefd LLC now owns 7,393 shares of the company's stock valued at $167,000 after purchasing an additional 1,052 shares during the period. Corient Private Wealth LLC increased its position in shares of Fresenius Medical Care by 3.4% during the fourth quarter. Corient Private Wealth LLC now owns 88,381 shares of the company's stock valued at $2,001,000 after acquiring an additional 2,918 shares during the last quarter. Natixis Advisors LLC acquired a new position in shares of Fresenius Medical Care in the 4th quarter worth approximately $332,000. HighTower Advisors LLC boosted its position in shares of Fresenius Medical Care by 7.9% during the 4th quarter. HighTower Advisors LLC now owns 17,890 shares of the company's stock worth $405,000 after purchasing an additional 1,305 shares during the period. Finally, Moran Wealth Management LLC raised its position in Fresenius Medical Care by 9.1% in the fourth quarter. Moran Wealth Management LLC now owns 254,710 shares of the company's stock valued at $5,767,000 after purchasing an additional 21,334 shares during the period. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Up 0.9 %

Shares of Fresenius Medical Care stock traded up $0.23 during trading on Friday, hitting $24.78. 293,191 shares of the stock were exchanged, compared to its average volume of 313,022. The stock has a market cap of $14.54 billion, a price-to-earnings ratio of 20.48, a price-to-earnings-growth ratio of 0.76 and a beta of 0.99. The firm's 50-day moving average price is $24.02 and its 200 day moving average price is $22.52. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. Fresenius Medical Care AG has a 12-month low of $17.93 and a 12-month high of $25.25.

Remove Ads

Analyst Ratings Changes

FMS has been the subject of a number of research analyst reports. Truist Financial raised their target price on Fresenius Medical Care from $23.00 to $25.00 and gave the company a "hold" rating in a report on Monday, January 6th. StockNews.com upgraded shares of Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Finally, Bank of America raised Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research report on Monday, December 2nd.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.